Untersuchungen �ber Abbau, Verteilung und Ausscheidung von Tritium-markiertem Cyclophosphamid im menschlichen Organismus

Ritzl, F.; Bolt, W; Nahrmann, H.

doi:10.1007/bf01492713

Cited by 10 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whether the oncolytic and hematological effects of cyclophosphamide are dependent wholly on the release of the nitrogen mustard amines in the tissues or whether intermediary metabolites also are active has not been determined5 although studies with the tritiated compound support the former concept. 16 T h e induction of remissions in acute leukemia has been reported by several investi-gators3. 4, 7, 9, 17,193 20 with different regimens of cyclophosphamide therapy.…”

Section: Yclophosphamide Has Been Used Exten-mentioning

confidence: 95%

Cyclophosphamide therapy in acute leukemia of childhood:Cooperative study conducted by members of children's cancer cooperative group A

Pierce¹,

Shore²,

Sitarz³

et al. 1966

Cancer

View full text Add to dashboard Cite

A controlled study of cyclophosphamide (Cytoxan) therapy in acute leukemia was conducted in 142 children in relapse to previous therapies. An oral regimen, using daily doses of 3mg/kg/day induced remission (complete or good partial) in 31.5% of the group; the intravenous regimen, using 15 mg/kg once weekly, induced similar remission in only 10.2% of the children so treated. All children who attained complete or partial remissions entered the study in a status of moderate disease while those in a more severe status of disease failed to attain satisfactory remissions to either regimen. Bone marrow remissions (A‐1 ratings) were attained in 27.5% of the group treated orally and in only 2.9% of those treated with the intravenous regimen. Leukopenia was the only significant hematologic sign of toxicity with either route of therapy. Signs of inflamation of the urinary tract occurred in approximately 10% of the patients. Nausea and vomiting were much more common with intravenous therapy. Cyclophosphamide, administered orally, is effective for the treatment of acute leukemia for children in early relapse but is not effective in patients in severe relapse to previous therapy.

show abstract

Section: Yclophosphamide Has Been Used Exten-mentioning

confidence: 95%

Cyclophosphamide therapy in acute leukemia of childhood:Cooperative study conducted by members of children's cancer cooperative group A

Pierce¹,

Shore²,

Sitarz³

et al. 1966

Cancer

View full text Add to dashboard Cite

show abstract

“…Nevertheless, the tumour counts for tumours in the medial half of the breast were greater than the counts in the lateral half. Furthermore, radio-isotope studies of cyclophosphamide tagged on the nitrogen-mustard side of the molecule have shown that there is selective uptake of the drug by tumour tissue (Ritzl, Bolt, and Nahrmann, 1962;Wilmans, Graul, and Hundeshagen, 1962). There is evidence that the drug remains inactive until the nitrogen-mustard part of the molecule is liberated.…”

Section: Discussionmentioning

confidence: 99%

Arterial perfusion of the breast with cytotoxic drugs

Lentin

Nambiar

Brennan

1967

Journal of British Surgery

View full text Add to dashboard Cite

SINCEHalsted described his technique of radical operation for cancer of the breast in 1907 there has been little significant improvement in the prognosis of this disease. This mood of complacency is not borne out by even the best figures. It is well to reflect that an 80 per cent 5-year survival in early cancer means that 20 out of every IOO women were probably beyond the stage of routine operative measures, even though the pathological report showed no spread to the axillary lymph-glands. Endeavouring to improve these results Urban (1964) has advocated a supra-radical mastectomy with en bloc resection of one-third of the sternum, the costal cartilages, and underlying lymph-nodes and parietal pleura, in addition to the conventional radical mastectomy.Dahl-Iversen and Tobiassen (1963) combined radical mastectomy with supraclavicular and parasternal dissection, and Haagensen and Cooley (1963)~ in an attempt to select only operable cases for radical mastectomy, have described a method of determining the extent of the disease by means of what they call a triple biopsy. These extended operations have not found favour in England and in the less experienced hands of general surgeons would undoubtedly lead to increased morbidity and operative mortality. Indeed, some surgeons who have advocated these extended procedures have now realized that their results were no better than with radical mastectomy (Cutler, 1965). For perhaps too long a time adjuvant radiotherapy was held to be the answer.When Paterson (1962) published his figures it became clear that radiotherapy following radical mastectomy showed no statistical difference in the crude mortality rate at 5 or 7 years between those so treated and those who were only carefully watched, and that in the long run it was better to withhold radiotherapy until secondary deposits develop. McWhirter (1955) advocates simple mastectomy and radiotherapy, and his initial results appear to be as good as those with radical mastectomy. Unfortunately other centres have not been able to reproduce his figures. It is therefore clear that radical mastectomy has stood the test of time as the best available treatment for operable cancer of the breast. The effect of cytotoxic drugs and hormones in prolonging life in the advanced cases of cancer is well known. Their real value must surely lie in their use in early operable cases. It seems reasonable therefore that their addition to operation is a logical procedure.This communication reports our experience with 62 cases of operable breast cancer treated by radical mastectomy with intra-arterial perfusion of cyclophosphamide. SELECTION AND PREPARATIONOF PATIENTS Only cases of clinical Stage I and Stage I1 breast cancers, i.e., clinically operable cases, are included in this series.Prior to operation haemoglobin, white-cell count, reticulocyte count, platelet count, and liver-function tests are carried out in addition to chest radiographs and routine skeletal screening. In our early cases IOO mg. of cyclophosphamide were administered orally a day b...

show abstract

“…Folgt man den Literaturangaben, so reichert sich das markierte Zyklophosphamid unterschiedlich in den Geweben an. Ritzl et al (11), Boit et al 1und Rabinowitz et al (10) konnten höhere Aktivitäten im Geschwulstgewebe als im normalen Organgewebe nachweisen. Sie schlössen daraus mit Vorbehalt auf eine selektive Anreicherung des markierten Zyklophosphamids im Tumorgewebe.…”

Section: üIskussionunclassified

Untersuchungen über den Einfluß von Heparinoid auf die Verteilung von 3H-markiertem und 32P-markiertem Zyklophosphamid in Organen von Ratten mit 3,4-Benzpyren-Sarkomen

Fahr¹,

Lorenz²,

Scheer³

1970

Nuklearmedizin

View full text Add to dashboard Cite

ZusammenfassungZiel der Untersuchung war es festzustellen, ob das Zytostatikum (Endoxan®) durch kombinierte Gabe mit dem Heparinoid GP 41 652 selektiv in Tumorzellen von Ratten mit 3,4-Benzpyren-Sarkomen eingeschleust wird.In einer ersten Versuchsreihe wurde Ratten 3H-markiertes Zyklophosphamid, welches in der Wirkgruppe markiert war, mit und ohne Heparinoid GP 41 652 intravenös injiziert. Die Tiere wurden nach 90 Minuten und 8 Stunden getötet. Die Aktivitätsverteilung in den Organen wurde mit einem Szintillationsspektrometer gemessen. Die höchste Aktivität wurde im Nieren- und Lebergewebe gefunden. Das Tumorgewebe zeigte eine geringere Aktivitätsspeicherung.In einer zweiten Versuchsreihe wurde den Ratten 32P-markiertes Zyklophosphamid injiziert, welches in der Transportgruppe markiert war. Auch hier fand man die höchste Aktivität im Nieren- und Lebergewebe. Eine selektive Anreicherung des Zytostatikums im Organ- und Tumorgewebe nach Zusatz von Heparinoid GP 41 652 konnte in keinem der Versuche gefunden werden.

show abstract

Untersuchungen �ber Abbau, Verteilung und Ausscheidung von Tritium-markiertem Cyclophosphamid im menschlichen Organismus

Cited by 10 publications

References 2 publications

Cyclophosphamide therapy in acute leukemia of childhood:Cooperative study conducted by members of children's cancer cooperative group A

Cyclophosphamide therapy in acute leukemia of childhood:Cooperative study conducted by members of children's cancer cooperative group A

Arterial perfusion of the breast with cytotoxic drugs

Untersuchungen über den Einfluß von Heparinoid auf die Verteilung von 3H-markiertem und 32P-markiertem Zyklophosphamid in Organen von Ratten mit 3,4-Benzpyren-Sarkomen

Contact Info

Product

Resources

About